PepGen prices common stock offering at $3.20 per share to raise $100m

PepGen Inc. (NASDAQ:PEPG) has priced an underwritten public offering of 31,250,000 shares at $3.20 per share, aiming to raise $100 million in gross proceeds to fund ongoing clinical development, including its FREEDOM-DM1 trials, and general corporate purposes. This capital raise is critical given the company's rapid cash burn despite holding more cash than debt, and it follows recent positive Phase 1 results for its myotonic dystrophy type 1 treatment, underscoring its efforts to advance its specialized oligonucleotide therapy pipeline.

Analysis

PepGen Inc. is executing a significant capital raise, pricing a public offering of 31.25 million shares at $3.20 per share to generate $100 million in gross proceeds. This move directly addresses a key operational risk noted in the report: a rapid cash burn rate, despite its current net cash position. The timing is strategic, coming on the heels of positive Phase 1 data for its FREEDOM-DM1 study, where its myotonic dystrophy type 1 treatment achieved a mean splicing correction of 53.7% across all patients. By securing funding now, management is leveraging positive clinical momentum to finance its next crucial development stages, including the ongoing FREEDOM-DM1 and FREEDOM2-DM1 trials. The offering, led by Leerink Partners and Stifel, effectively de-risks the company's financial runway, allowing it to focus on advancing its Enhanced Delivery Oligonucleotide platform towards key clinical milestones.

Key Decisions for Investors

• Investors should view this as a strategic financing that extends the company's operational runway, weighing the positive clinical de-risking from the FREEDOM-DM1 Phase 1 results against the near-term shareholder dilution from the new share issuance.
• Monitor cash burn rate post-offering and track enrollment and progress updates for the pivotal FREEDOM-DM1 and FREEDOM2-DM1 trials, as execution on these programs is now the primary driver of value.
• Consider the $3.20 offering price as a significant near-term valuation benchmark, reflecting the current institutional sentiment after the recent positive clinical data.